ARID1A and clear cell adenocarcinoma: Because we could not use serial sections for both immunohistochemical analysis in this study and target gene sequencing in the previous study, we validated the ARID1A mutation status of FFPE tissue samples in nine clear cell carcinoma samples with ARID1A truncating mutations.